CFTR and cystic fibrosis: We recently reported that apart from its CFTR rescuing property, GSNO augmentation by using either GSNO or a GSNOR-inhibitor (N6022) effectively diminished CS-induced inflammatory-oxidative stress and also corrected the autophagy impairment (Bodas et al., 2017), thus targeting the underlying cause of CFTR dysfunction and resulting CF lung disease pathogenesis and progression.